28 Participants Needed

Cabozantinib + Pembrolizumab for Melanoma

Yousef Zakharia, MD profile photo
Overseen ByYousef Zakharia, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

Will I have to stop taking my current medications?

The trial requires a 2-week washout period (time without taking certain medications) for those who have taken BRAF and/or MEK inhibitors. Additionally, you cannot take certain medications like strong CYP3A4 inducers or inhibitors close to the start of the trial. Other medications may also need to be stopped, but the protocol does not specify all details.

What data supports the effectiveness of the drug pembrolizumab for melanoma?

Pembrolizumab has been shown to improve treatment outcomes in advanced melanoma, performing better than another drug called ipilimumab. It has also been approved for use in patients with advanced melanoma, showing it can help control the disease.12345

Is the combination of Cabozantinib and Pembrolizumab safe for treating melanoma?

Pembrolizumab, also known as KEYTRUDA, has been shown to be generally safe in humans with advanced melanoma, with common side effects including fatigue, rash, itching, and diarrhea. Less common side effects can include thyroid issues, inflammation of the colon, liver, or lungs. While specific safety data for the combination with Cabozantinib is not provided, Pembrolizumab alone has a favorable safety profile.26789

How is the drug combination of Cabozantinib and Pembrolizumab unique for treating melanoma?

The combination of Cabozantinib and Pembrolizumab is unique because it pairs a tyrosine kinase inhibitor (Cabozantinib) with an immune checkpoint inhibitor (Pembrolizumab), potentially enhancing the immune system's ability to fight melanoma by targeting different pathways. This approach is novel compared to traditional treatments that often focus on a single mechanism.1261011

What is the purpose of this trial?

This trial is testing a combination of two drugs to treat adults with advanced melanoma that cannot be surgically removed. One drug stops cancer cells from growing, and the other helps the immune system attack the cancer. The combination of pembrolizumab and ipilimumab is being tested for its effectiveness and safety in treating advanced melanoma.

Research Team

JR

John Rieth, MD

Principal Investigator

University of Iowa

Eligibility Criteria

Adults with advanced melanoma who can swallow pills, have measurable lesions, and haven't had certain treatments for their cancer recently. They must understand the study and agree to provide tissue samples. Women of childbearing age need a negative pregnancy test.

Inclusion Criteria

I can care for myself and have a life expectancy of more than 12 weeks.
I haven't been treated for advanced melanoma, except possibly BRAF/MEK inhibitors.
My melanoma cannot be removed by surgery and is either stage IIIc or IV.
See 8 more

Exclusion Criteria

I have not had any cancer other than skin, cervical, or in situ cancers in the last 2 years.
I haven't taken any tyrosine kinase inhibitor medication in the last 2 weeks.
I have had treatments targeting PD-1, PD-L1, or PD-L2 for advanced melanoma, but not within the last 6 months if it was for preventing cancer return.
See 18 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 1b Treatment

Establish the recommended Phase 2 dose of cabozantinib in combination with pembrolizumab and assess safety and tolerability

Up to 2 years
Pembrolizumab administered every 3 weeks

Phase 2 Treatment

Evaluate the preliminary efficacy of the established dose of cabozantinib in combination with pembrolizumab

Up to 2 years
Pembrolizumab administered every 3 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Cabozantinib
  • Pembrolizumab
Trial Overview The trial is testing the combination of two drugs, Cabozantinib and Pembrolizumab, to see how safe they are together and if they work well against advanced melanoma.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Cabozantinib and pembrolizumabExperimental Treatment2 Interventions
Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day. Pembrolizumab will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks.

Cabozantinib is already approved in European Union, United States, Canada, Japan for the following indications:

🇪🇺
Approved in European Union as Cabometyx for:
  • Renal cell carcinoma
  • Hepatocellular carcinoma
🇺🇸
Approved in United States as Cabometyx for:
  • Renal cell carcinoma
  • Hepatocellular carcinoma
🇨🇦
Approved in Canada as Cabometyx for:
  • Renal cell carcinoma
  • Hepatocellular carcinoma
🇯🇵
Approved in Japan as Cabometyx for:
  • Renal cell carcinoma

Find a Clinic Near You

Who Is Running the Clinical Trial?

John Rieth

Lead Sponsor

Trials
4
Recruited
70+

Yousef Zakharia

Lead Sponsor

Trials
5
Recruited
160+

University of Iowa

Collaborator

Trials
486
Recruited
934,000+

Exelixis

Industry Sponsor

Trials
126
Recruited
20,500+
Michael M. Morrissey profile image

Michael M. Morrissey

Exelixis

Chief Executive Officer since 2010

PhD in Chemistry from Harvard University, BSc in Chemistry from the University of Wisconsin

Vicki L. Goodman profile image

Vicki L. Goodman

Exelixis

Chief Medical Officer since 2022

MD

Findings from Research

In a post hoc analysis of the KEYNOTE-006 study involving 555 patients with advanced melanoma, both ipilimumab and BRAF ± MEK inhibitors showed antitumor activity as subsequent therapies after pembrolizumab, with overall response rates (ORR) of 17.5% for ipilimumab and 30.5% for BRAF ± MEK inhibitors.
Patients who had not previously received BRAF ± MEK inhibitors showed a significantly higher ORR of 43.2% when treated with these agents after pembrolizumab, indicating that prior treatment status may influence the effectiveness of subsequent therapies.
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.Long, GV., Arance, A., Mortier, L., et al.[2022]
Pembrolizumab (Keytruda) is the first anti-PD-1 therapy approved in the US for treating advanced malignant melanoma, specifically for patients who have progressed after prior treatments.
It is designed to target the PD-1 protein, enhancing the immune system's ability to fight cancer, and is currently under review for approval in the EU.
Pembrolizumab: first global approval.Poole, RM.[2021]
In a randomized trial comparing FDA-approved immune checkpoint inhibitors for advanced melanoma, pembrolizumab showed significantly better treatment outcomes than ipilimumab.
This study is notable as it is the first to directly compare these two therapies as first-line treatments, highlighting pembrolizumab's potential as a more effective option for patients.
Pembrolizumab superior to ipilimumab in melanoma.[2017]

References

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. [2022]
Pembrolizumab: first global approval. [2021]
Pembrolizumab superior to ipilimumab in melanoma. [2017]
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. [2020]
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. [2022]
Pembrolizumab in the management of metastatic melanoma. [2020]
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma. [2022]
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). [2020]
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. [2023]
Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. [2017]
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security